|
DNMT inhibitors
|
|
Arsenic trioxide
|
Clinical Trials
|
[112]
|
|
5- azacytidine (Vidaza, Celgene)
|
USFDA Approved
|
[47]
|
|
5-aza-2′-deoxycitidine (Decitabine, Dacogen, SuperGen)
|
USFDA Approved
|
[47]
|
|
MG98
|
Clinical trials
|
[122]
|
|
HDAC inhibitors
|
|
LAQ-824/LBH 589 (Farydak, panobinostat)
|
USFDA Approved
|
[122]
|
|
PXD-101(Belinostat)
|
Clinical trials
|
[122]
|
|
Valproic acid (Mg valproate)
|
Clinical trials
|
[122]
|
|
Suberoylanilide hydroxamic acid (vorinostat, SAHA)
|
USFDA Approved
|
[122]
|
|
FK-228 (romidepsin)
|
USFDA Approved
|
[121]
|
|
Phenylbutyrate
|
Clinical trials
|
[122]
|
|
MS-275 (entinostat)
|
Clinical trials
|
[150, 151]
|
|
CI-994
|
Clinical trials
|
[90, 120]
|
|
MGCD-0103 (Mocetinostat)
|
Clinical trials
|
[145]
|
|
JNJ-26481585 (Quisinostat)
|
Clinical trials
|
[146, 147]
|
|
HMT inhibitors
|
|
EPZ-6438 (E7438, Epizyme)
|
Clinical trials
|
[62, 148]
|
|
3-Deazaneplanocin (DZNep)
|
Clinical trials
|
[58]
|
|
EPZ-5676
|
Clinical trials
|
[62]
|
|
EPZ-5687
|
Preclinical
|
[58]
|
|
GSK-343
|
Preclinical
|
[58]
|
